A Phase 1/2 interventional study of sotorasib and Anti PD-1/L1 in KRAS p.G12C Mutant Advanced Solid Tumors, sponsored by Amgen. Completed at 133 sites in 16 countries. Open to participants aged 18 Years to 100 Years. Per ClinicalTrials.gov, last updated 2026-06-30.
Sponsored by Amgen · Phase 1/2, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Evaluate the safety and tolerability of sotorasib in adult subjects with KRAS p.G12C mutant advanced solid tumors.
Estimate the maximum tolerated dose (MTD) and/or a recommended phase 2 dose (RP2D) in adult subjects with KRAS p.G12C mutant advanced solid tumors.
Amgen is the lead sponsor of 1,047 studies on the registry; 51 are open to participants now.
Of its 246 completed or terminated interventional studies of FDA-regulated products, 166 (67%) have results posted.
Counted across the registry records on this site, refreshed daily.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
The diagnosis was confirmed by looking at a sample under a microscope: tissue from a biopsy or surgery (histology), or cells from a fluid or needle sample (cytology).
Your pathology report is the document that shows this.
Cancer that has spread from where it began to other parts of the body. “Metastatic” cancer is cancer that has spread this way.
Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.
Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.
Cancer deposits in the brain from a cancer that started elsewhere in the body (CNS metastases include the spinal cord).
Studies differ: some leave out any brain metastases, some accept ones treated and stable for some weeks. Check what this study allows.
Histologically or cytologically confirmed
The diagnosis was confirmed by looking at a sample under a microscope: tissue from a biopsy or surgery (histology), or cells from a fluid or needle sample (cytology).
Your pathology report is the document that shows this.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Metastases
Cancer that has spread from where it began to other parts of the body. “Metastatic” cancer is cancer that has spread this way.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Cancer (malignancy)
Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.
Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Brain metastases
Cancer deposits in the brain from a cancer that started elsewhere in the body (CNS metastases include the spinal cord).
Studies differ: some leave out any brain metastases, some accept ones treated and stable for some weeks. Check what this study allows.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Cohorts with food effect and alternative dosing regimens Enrollment into the dose exploration cohorts may be from any eligible solid tumor type. Dose escalation will begin with 2-4 subjects treated at the lowest planned dose level of 180 mg. If no DLT is observed, dose escalation will continue to the next planned dose cohort
Drug: sotorasib
Upon completing the dose exploration part of the study, dose expansion may proceed with 3 groups consisting of subjects with KRAS p.G12C mutant advanced solid tumors. Dose expansion in these 3 groups may be done concurrently
Drug: sotorasib
Additional subjects will be enrolled into the combination arm with sotorasib in combination with an anti (PD-1/L1)
Drug: sotorasib · Drug: Anti PD-1/L1
Separate cohort of part 1 dose expansion subjects to evaluate the safety and clinical activity of sotorasib administered orally once daily in subjects with previously untreated advanced non-small cell lung cancer (NSCLC). Drug-drug interaction will be evaluated in 6 of the subjects enrolled in the treatment naive cohort by adding Midazolam alone on Day -1 and in combination with sotorasib on Day 15 of Cycle 1, where each cycle is 21 days.
Drug: sotorasib · Drug: Midazolam
Subjects with NSCLC will be enrolled in a dose comparison study evaluating safety and efficacy
Drug: sotorasib
BID 2L+solid tumors (fed state)
Drug: sotorasib
Primary: Number of subjects with treatment-emergent adverse events
Treatment-emergent adverse events will be a primary outcome measure for the following groups: * Phase 1 Dose Exploration Part 1 monotherapy * Phase 1 Dose Expansion Part 2 monotherapy * Phase 1 combination arm with sotorasib and anti PD-1/L1 * Phase 1 monotherapy treatment naïve advanced NSCLC * Phase 2 monotherapy dose comparison
Time frame: 24 Months
Primary: Number of subjects with treatment-related adverse events
Treatment-related adverse events will be a primary outcome measure for the following groups: * Phase 1 Dose Exploration Part 1 monotherapy * Phase 1 Dose Expansion Part 2 monotherapy * Phase 1 combination arm with sotorasib and anti PD-1/L1 * Phase 1 monotherapy treatment naïve advanced NSCLC
Time frame: 24 Months
Primary: Number of subjects with grade ≥3 treatment-emergent adverse events
Grade ≥3 treatment-emergent adverse events will be a primary outcome measure in the following group: \- Phase 2 monotherapy dose comparison
Time frame: 24 Months
Primary: Number of subjects with serious adverse events
Serious adverse events will be a primary outcome measure in the following group: \- Phase 2 monotherapy dose comparison
Time frame: 24 Months
Primary: Number of subjects with adverse events of interest
Adverse events of interest will be a primary outcome measure in the following group: \- Phase 2 monotherapy dose comparison
Time frame: 24 Months
Primary: Number of subjects with clinically significant changes in vital signs
Vital signs will be a primary outcome measure for the following groups: * Phase 1 Dose Exploration Part 1 monotherapy * Phase 1 Dose Expansion Part 2 monotherapy * Phase 1 combination arm with sotorasib and anti PD-1/L1 * Phase 1 monotherapy treatment naïve advanced NSCLC
Time frame: Baseline to 24 Months
Primary: Number of subjects with clinically significant changes in physical examination results
Physical examinations will be a primary outcome measure for the following groups: * Phase 1 Dose Exploration Part 1 monotherapy * Phase 1 Dose Expansion Part 2 monotherapy * Phase 1 combination arm with sotorasib and anti PD-1/L1
Time frame: Baseline to 24 Months
Primary: Number of subjects with clinically significant changes on electrocardiograms (ECGs)
ECGs will be a primary outcome measure for the following groups: * Phase 1 Dose Exploration Part 1 monotherapy * Phase 1 Dose Expansion Part 2 monotherapy * Phase 1 combination arm with sotorasib and anti PD-1/L1 * Phase 1 monotherapy treatment naïve advanced NSCLC
Time frame: Baseline to 24 Months
Primary: Number of subjects with clinically significant changes in clinical laboratory values
Abnormal clinical laboratory values will be a primary outcome measure for the following groups: * Phase 1 Dose Exploration Part 1 monotherapy * Phase 1 Dose Expansion Part 2 monotherapy * Phase 1 combination arm with sotorasib and anti PD-1/L1 * Phase 1 monotherapy treatment naïve advanced NSCLC
Time frame: Baseline to 24 Months
Primary: Number of subjects with dose-limiting toxicities (DLTs)
DLTs will be a primary outcome measure for the following groups: * Phase 1 Dose Exploration Part 1 monotherapy * Phase 1 Dose Expansion Part 2 monotherapy * Phase 1 combination arm with sotorasib and anti PD-1/L1 * Phase 1 monotherapy treatment naïve advanced NSCLC
Time frame: 21 Days
Primary: Objective response rate (ORR) as assessed by RECIST 1.1 criteria
ORR will be a primary outcome measure in the following group: * Phase 1 monotherapy treatment naïve advanced NSCLC * Phase 2 monotherapy * Phase 2 monotherapy dose comparison
Time frame: 24 Months
Primary: Duration of response (DOR) as assessed by RECIST 1.1 criteria
DOR will be a primary outcome measure in the following group: \- Phase 1 monotherapy treatment naïve advanced NSCLC
Time frame: 24 Months
Primary: Disease control as assessed by RECIST 1.1 criteria
Disease control will be a primary outcome measure in the following group: \- Phase 1 monotherapy treatment naïve advanced NSCLC
Time frame: 24 Months
Primary: Duration of stable disease (SD) as assessed by RECIST 1.1 criteria
Duration of SD will be a primary outcome measure in the following group: \- Phase 1 monotherapy treatment naïve advanced NSCLC
Time frame: 24 Months
Primary: Time to response (TTR) as assessed by RECIST 1.1 criteria
TTR will be a primary outcome measure in the following group: \- Phase 1 monotherapy treatment naïve advanced NSCLC
Time frame: 24 Months
Secondary: Plasma concentration (Cmax) of sotorasib
Cmax will be a secondary outcome measure for the following groups: * Phase 1 Dose Exploration Part 1 monotherapy * Phase 1 Dose Expansion Part 2 monotherapy * Phase 2 monotherapy * Phase 1 combination arm with sotorasib and anti PD-1/L1 * Phase 1 monotherapy treatment naïve advanced NSCLC * Phase 2 monotherapy dose comparison
Time frame: 15 Weeks
Secondary: Plasma concentration (Cmax) of midazolam
Cmax of midazolam will be a secondary outcome measure for the subgroup of subjects who were administered midazolam in the following group: \- Phase 1 monotherapy treatment naïve advanced NSCLC
Time frame: 16 Days
Secondary: Time to achieve Cmax (Tmax) of sotorasib
Tmax will be a secondary outcome measure for the following groups: * Phase 1 Dose Exploration Part 1 monotherapy * Phase 1 Dose Expansion Part 2 monotherapy * Phase 2 monotherapy * Phase 1 combination arm with sotorasib and anti PD-1/L1 * Phase 1 monotherapy treatment naïve advanced NSCLC
Time frame: 15 Weeks
Secondary: Area under the plasma concentration-time curve (AUC) of sotorasib
AUC will be a secondary outcome measure for the following groups: * Phase 1 Dose Exploration Part 1 monotherapy * Phase 1 Dose Expansion Part 2 monotherapy * Phase 2 monotherapy * Phase 1 combination arm with sotorasib and anti PD-1/L1 * Phase 1 monotherapy treatment naïve advanced NSCLC * Phase 2 monotherapy dose comparison
Time frame: 15 Weeks
Secondary: Area under the plasma concentration-time curve (AUC) of midazolam
AUC of midazolam will be a secondary outcome measure for the subgroup of subjects who were administered midazolam in the following group: \- Phase 1 monotherapy treatment naïve advanced NSCLC
Time frame: 16 Days
Secondary: Clearance of midazolam from the plasma
Clearance of midazolam from the plasma will be a secondary outcome measure for the subgroup of subjects who were administered midazolam in the following group: \- Phase 1 monotherapy treatment naïve advanced NSCLC
Time frame: 16 Days
Secondary: Terminal half-life (t1/2) of midazolam
t1/2 of midazolam will be a secondary outcome measure for the subgroup of subjects who were administered midazolam in the following group: \- Phase 1 monotherapy treatment naïve advanced NSCLC
Time frame: 16 Days
Secondary: Objective response rate (ORR) as assessed by RECIST 1.1 criteria
ORR will be a secondary outcome measure for the following groups: * Phase 1 Dose Exploration Part 1 monotherapy * Phase 1 Dose Expansion Part 2 monotherapy * Phase 1 combination arm with sotorasib and anti PD-1/L1
Time frame: 24 Months
Secondary: Duration of response (DOR) as assessed by RECIST 1.1 criteria
DOR will be a secondary outcome measure for the following groups: * Phase 1 Dose Exploration Part 1 monotherapy * Phase 1 Dose Expansion Part 2 monotherapy * Phase 2 monotherapy * Phase 1 combination arm with sotorasib and anti PD-1/L1 * Phase 2 monotherapy dose comparison
Time frame: 24 Months
Secondary: Disease control as assessed by RECIST 1.1 criteria
DOR will be a secondary outcome measure for the following groups: * Phase 1 Dose Exploration Part 1 monotherapy * Phase 1 Dose Expansion Part 2 monotherapy * Phase 2 monotherapy * Phase 1 combination arm with sotorasib and anti PD-1/L1 * Phase 2 monotherapy dose comparison
Time frame: 24 Months
Secondary: Progression-free survival (PFS) as assessed by RECIST 1.1 criteria
PFS will be a secondary outcome measure for the following groups: * Phase 1 Dose Exploration Part 1 monotherapy * Phase 1 Dose Expansion Part 2 monotherapy * Phase 2 monotherapy * Phase 1 combination arm with sotorasib and anti PD-1/L1 * Phase 2 monotherapy dose comparison * Phase 1 monotherapy treatment naïve advanced NSCLC
Time frame: 24 Months
Secondary: Duration of stable disease (SD) as assessed by RECIST 1.1 criteria
Duration of SD will be a secondary outcome measure for the following groups: * Phase 1 Dose Exploration Part 1 monotherapy * Phase 1 Dose Expansion Part 2 monotherapy * Phase 1 combination arm with sotorasib and anti PD-1/L1
Time frame: 24 Months
Secondary: Depth of response (best percentage change from baseline in lesion sum diameters) as assessed by RECIST 1.1 criteria
Depth of response will be a secondary outcome measure for the following group: \- Phase 2 monotherapy dose comparison
Time frame: Baseline to 24 Months
Secondary: Time to response (TTR) as assessed by RECIST 1.1 criteria
DOR will be a secondary outcome measure for the following groups: * Phase 1 Dose Exploration Part 1 monotherapy * Phase 1 Dose Expansion Part 2 monotherapy * Phase 2 monotherapy * Phase 1 combination arm with sotorasib and anti PD-1/L1 * Phase 2 monotherapy dose comparison
Time frame: 24 Months
Secondary: Overall survival (OS)
OS will be a secondary outcome measure for the following groups: * Phase 1 Dose Exploration Part 1 monotherapy * Phase 1 Dose Expansion Part 2 monotherapy * Phase 2 monotherapy * Phase 1 combination arm with sotorasib and anti PD-1/L1 * Phase 2 monotherapy dose comparison * Phase 1 monotherapy treatment naïve advanced NSCLC
Time frame: 24 Months
Secondary: sotorasib exposure and QTc interval relationship
sotorasib exposure and QTc interval relationship will be a secondary outcome measure for the following groups: * Phase 1 Dose Exploration Part 1 monotherapy * Phase 1 Dose Expansion Part 2 monotherapy
Time frame: 24 Months
Secondary: Progression-free survival (PFS) at 6 months
PFS at 6 months will be a secondary outcome measure for the following group: \- Phase 2 monotherapy
Time frame: 6 Months
Secondary: Progression-free survival (PFS) at 12 months
PFS at 12 months will be a secondary outcome measure for the following group: \- Phase 2 monotherapy
Time frame: 12 Months
Secondary: Overall survival (OS) at 12 months
OS at 12 months will be a secondary outcome measure for the following group: \- Phase 2 monotherapy
Time frame: 12 Months
Secondary: Number of subjects with treatment-emergent adverse events
Treatment-emergent adverse events will be a secondary outcome measure for the following group: \- Phase 2 monotherapy
Time frame: 24 Months
Secondary: Number of subjects with grade ≥3 treatment-emergent adverse events
Grade ≥3 treatment-emergent adverse events will be a secondary outcome measure for the following group: \- Phase 2 monotherapy
Time frame: 24 Months
Secondary: Impact of treatment on disease-related symptoms and health related quality of life (HRQOL) as assessed by EORTC QLQ-C30
Impact of treatment on disease-related symptoms and HRQOL will be a secondary outcome measure for the following group: \- Phase 2 monotherapy dose comparison
Time frame: 24 Months
Secondary: Impact of treatment on disease-related symptoms and HRQOL as assessed by disease-specific modules Quality-of-Life Questionnaire Lung Cancer Module (QLQ LC13)
Impact of treatment on disease-related symptoms and HRQOL will be a secondary outcome measure for the following group: \- Phase 2 monotherapy dose comparison
Time frame: 24 Months
Secondary: Impact of treatment on disease-related symptoms and HRQOL as assessed by non-small cell lung cancer symptom assessment questionnaire (NSCLC SAQ) for NSCLC
Impact of treatment on disease-related symptoms and HRQOL will be a secondary outcome measure for the following group: \- Phase 2 monotherapy dose comparison
Time frame: 24 Months
Secondary: Impact of treatment on disease-related symptoms and HRQOL as assessed by Patient Global Impression of Severity (PGIS)
Impact of treatment on disease-related symptoms and HRQOL will be a secondary outcome measure for the following group: \- Phase 2 monotherapy dose comparison
Time frame: 24 Months
Secondary: Impact of treatment on disease-related symptoms and HRQOL as assessed by Patient Global Impression of Change (PGIC) in cough, dyspnea and chest pain for NSCLC
Impact of treatment on disease-related symptoms and HRQOL will be a secondary outcome measure for the following group: \- Phase 2 monotherapy dose comparison
Time frame: 24 Months
Secondary: Treatment-related symptoms and impact on the subject as assessed by EORTC QLQ-C30
Treament related symptoms and impact on the subject will be a secondary outcome measure for the following group: \- Phase 2 monotherapy dose comparison
Time frame: 24 Months
Secondary: Treatment-related symptoms and impact on the subject as assessed by selected questions from the Patient-reported Outcome of the Common Terminology Criteria for Adverse Events (PRO-CTCAE library)
Treatment-related symptoms and impact on the subject will be a secondary outcome measure for the following group: \- Phase 2 monotherapy dose comparison
Time frame: 24 Months
Secondary: Treatment-related symptoms and impact on the subject as assessed by a single item about symptom bother, item GP5 of the Functional Assessment of Cancer Therapy - General (FACT-G)
Treatment-related symptoms and impact on the subject will be a secondary outcome measure for the following group: \- Phase 2 monotherapy dose comparison
Time frame: 24 Months
Secondary: Change from baseline in physical function as assessed by EORTC QLQ-C30
Treatment-related symptoms and impact on the subject will be a secondary outcome measure for the following group: \- Phase 2 monotherapy dose comparison
Time frame: Baseline to 24 Months
Showing the first 100 of 133 sites across 16 countries. Choose a country and city above to see the rest.
Plan to share: Yes — De-identified individual patient data for variables necessary to address the specific research question in an approved data sharing request
Supporting information: Study protocol, Statistical analysis plan, Informed consent form, Clinical study report
Time frame: Data sharing requests relating to this study will be considered beginning 18 months after the study has ended and either 1) the product and indication have been granted marketing authorization in both the US and Europe or 2) clinical development for the product and/or indication discontinues and the data will not be submitted to regulatory authorities. There is no end date for eligibility to submit a data sharing request for this study.
Access criteria: Qualified researchers may submit a request containing the research objectives, the Amgen product(s) and Amgen study/studies in scope, endpoints/outcomes of interest, statistical analysis plan, data requirements, publication plan, and qualifications of the researcher(s). In general, Amgen does not grant external requests for individual patient data for the purpose of re-evaluating safety and efficacy issues already addressed in the product labelling. Requests are reviewed by a committee of internal advisors. If not approved, a Data Sharing Independent Review Panel will arbitrate and make the final decision. Upon approval, information necessary to address the research question will be provided under the terms of a data sharing agreement. This may include anonymized individual patient data and/or available supporting documents, containing fragments of analysis code where provided in analysis specifications. Further details are available at the URL below.
Data sharing details ↗ · www.amgen.com
Ran from Aug 2018 to primary completion in May 2026, 93 months.
How these figures are worked out, and which studies are left out of them.
This study is completed, as verified in Jun 2026. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drug tested here: Sotorasib